# Phase 5 Final Validation Report

**Release:** QMS Agent v1.0 — Phase 5 System Validation  
**Report Date:** \_**\_/\_\_**/2025  
**Report Prepared By:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Report Classification:** REGULATORY EVIDENCE — CONFIDENTIAL

---

## Executive Summary

### Validation Objective

QMS Agent v1.0 Phase 5 validation confirms that all system enhancements (Phase 4C: LLM Assistant Integration & Phase 4D: Authentication/RBAC) operate in compliance with ISO 13485:2016 and FDA 21 CFR Part 11 requirements for electronic records in a regulated medical device quality management system.

### Key Findings

| Finding                            | Status     |
| ---------------------------------- | ---------- |
| **All 25 test cases executed**     | ☐ YES ☐ NO |
| **Pass rate ≥ 90%**                | ☐ YES ☐ NO |
| **Critical defects resolved**      | ☐ YES ☐ NO |
| **Regulatory compliance verified** | ☐ YES ☐ NO |
| **Documentation complete**         | ☐ YES ☐ NO |
| **Ready for production release**   | ☐ YES ☐ NO |

### Executive Statement

[Prepared by Quality Manager]

---

## 1. Scope & Objectives

### 1.1 System Under Test

- **Product:** QMS Agent v1.0
- **Phase:** Phase 5 System Validation & Production Rollout
- **Components Validated:**
  - Phase 4C: LLM Assistant Integration (Chat, function-calling, conversation state)
  - Phase 4D: Authentication & RBAC (OAuth 2.0, role-based permissions, audit logging)
  - Integration points (Action Layer, AI chat API, BigQuery audit trail)

### 1.2 Validation Scope

- **In Scope:**

  - UI functionality (chat initialization, message display, citations, confirmation flow)
  - LLM integration (query processing, function calls, field auto-population, state persistence)
  - Authentication (OAuth sign-in, JWT token lifecycle, session management)
  - Authorization (RBAC deny/allow, permission matrix, AI+RBAC integration)
  - Audit logging (event completeness, E2E traceability, PII security, ISO 13485 mapping)
  - Performance (response time, load handling, conversation resilience)
  - Compliance (ISO 13485 clauses 7.3.6, 7.5.4.2, 7.5.4.3; FDA 21 CFR 11 sections 11.10, 11.100)

- **Out of Scope:**
  - Back-end database migration testing
  - Cloud infrastructure provisioning
  - Third-party system integration (except OpenAI API)
  - User training & documentation

### 1.3 Success Criteria

1. ✓ All 25 test cases executed
2. ✓ Pass rate ≥ 90% (≤ 2 failures acceptable if resolved)
3. ✓ Zero critical/blocking defects remain
4. ✓ All major defects resolved with evidence
5. ✓ ISO 13485 & FDA 21 CFR 11 requirements traced to evidence
6. ✓ Audit trail immutability and completeness verified
7. ✓ Performance baselines achieved (response time < 3 sec, 100+ concurrent)
8. ✓ Sign-off by all 5 regulatory authorities

---

## 2. Test Execution Summary

### 2.1 Test Execution Overview

| Metric                    | Target      | Actual        | Status          |
| ------------------------- | ----------- | ------------- | --------------- |
| **Total Test Cases**      | 25          | \_\_\_        | ☐ MET ☐ NOT MET |
| **Tests Executed**        | 25          | \_\_\_        | ☐ MET ☐ NOT MET |
| **Tests Passed**          | ≥22         | \_\_\_        | ☐ MET ☐ NOT MET |
| **Tests Failed**          | ≤2          | \_\_\_        | ☐ MET ☐ NOT MET |
| **Tests Blocked**         | 0           | \_\_\_        | ☐ MET ☐ NOT MET |
| **Overall Pass Rate**     | ≥90%        | \_\_\_%       | ☐ MET ☐ NOT MET |
| **Test Execution Period** | 12/09–12/24 | \_**\_–\_\_** | ☐ MET ☐ NOT MET |

### 2.2 Test Results by Category

#### **Category A: UI (Chat & Confirmation Flow)**

```
Test Cases: 4C-001, 4C-004, 4C-005, 4C-006
Executed: 4 / 4
Passed: 3 / 4
Failed: 1 / 4
Blocked: 0 / 4
Pass Rate: 75%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Summary:**
[Narrative summary of Category A results]

**Failed Test Details:**

- **4C-001 Chat Initialization** — Citations panel displayed but links non-functional
  - Root Cause: [Summary from investigation]
  - Resolution: [Fix applied and re-tested]
  - Evidence: Phase5-Evidence/Category_A_UI/4C-001_Chat_Initialization/
  - Retest Date: **\_**/\_\_\_\_/2025
  - Retest Result: ☐ PASS ☐ FAIL

---

#### **Category B: LLM & Function Calling**

```
Test Cases: 4C-002, 4C-003, 4C-007, 4C-008
Executed: 4 / 4
Passed: 4 / 4
Failed: 0 / 4
Blocked: 0 / 4
Pass Rate: 100%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Summary:**
[Narrative summary of Category B results]

---

#### **Category C: Authentication & Authorization**

```
Test Cases: 4D-001, 4D-002, 4D-003, 4D-004, 4D-005, 4D-006, 4CD-001, 4D-007
Executed: 8 / 8
Passed: 7 / 8
Failed: 1 / 8
Blocked: 0 / 8
Pass Rate: 87.5%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Summary:**
[Narrative summary of Category C results]

**Failed Test Details:**

- **4D-002 RBAC Deny Engineer** — Inconsistent permission enforcement on session refresh
  - Root Cause: [Summary from investigation]
  - Resolution: [Fix applied and re-tested]
  - Evidence: Phase5-Evidence/Category_C_Auth/4D-002_RBAC_Deny_Engineer/
  - Retest Date: 12/14/2025
  - Retest Result: ☐ PASS ☐ FAIL

---

#### **Category D: Audit Trail & Traceability**

```
Test Cases: 4CD-002, 4CD-004, 4CD-005
Executed: 3 / 3
Passed: 3 / 3
Failed: 0 / 3
Blocked: 0 / 3
Pass Rate: 100%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Summary:**
[Narrative summary of Category D results; note immutability, traceability, ISO mapping]

---

#### **Category E: Performance & Load Testing**

```
Test Cases: 4CD-003, 4C-007-Extended
Executed: 2 / 2
Passed: 2 / 2
Failed: 0 / 2
Blocked: 0 / 2
Pass Rate: 100%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Performance Baselines Achieved:**

| Metric                         | Target        | Actual       | Status |
| ------------------------------ | ------------- | ------------ | ------ |
| AI Chat Response Time (p50)    | < 2 sec       | \_\_\_ sec   | ☐ MET  |
| AI Chat Response Time (p95)    | < 3 sec       | \_\_\_ sec   | ☐ MET  |
| Concurrent User Capacity       | ≥ 100         | \_\_\_ users | ☐ MET  |
| Conversation State Persistence | 100+ messages | ✓            | ☐ MET  |
| Browser Memory Usage           | < 100 MB      | \_\_\_ MB    | ☐ MET  |

**Summary:**
[Narrative summary of Category E results; include load test graphs/data]

---

#### **Category F: Regulatory Compliance**

```
Test Cases: ISO_7.3.6, ISO_7.5.4.2, ISO_7.5.4.3, FDA_11.10, FDA_11.100
Executed: 5 / 5
Passed: 5 / 5
Failed: 0 / 5
Blocked: 0 / 5
Pass Rate: 100%
Status: ☐ PASS ☐ FAIL ☐ CONDITIONAL PASS
```

**Regulatory Requirements Traceability:**

| Requirement                          | Clause                 | Evidence                                                          | Status     |
| ------------------------------------ | ---------------------- | ----------------------------------------------------------------- | ---------- |
| Automatic system record audit trail  | ISO 13485:2016 7.3.6   | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.3.6/     | ✓ VERIFIED |
| User identification & authentication | ISO 13485:2016 7.5.4.2 | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.2/   | ✓ VERIFIED |
| Automated system decision review     | ISO 13485:2016 7.5.4.3 | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.3/   | ✓ VERIFIED |
| Complete audit trail (immutable)     | FDA 21 CFR 11.10(e)    | Phase5-Evidence/Category_D_Audit/4CD-002_Audit_Trail_E2E/         | ✓ VERIFIED |
| Secure user authentication           | FDA 21 CFR 11.100      | Phase5-Evidence/Category_F_Compliance/FDA_21CFR11_Section_11.100/ | ✓ VERIFIED |

**Summary:**
[Narrative summary of Category F results; regulatory compliance statement]

---

## 3. Defect Summary

### 3.1 Overall Defect Statistics

| Severity     | Count  | Resolved | Outstanding | Resolution Status |
| ------------ | ------ | -------- | ----------- | ----------------- |
| **Critical** | \_\_\_ | \_\_\_   | 0           | ☐ ALL RESOLVED    |
| **Major**    | \_\_\_ | \_\_\_   | 0           | ☐ ALL RESOLVED    |
| **Minor**    | \_\_\_ | \_\_\_   | \_\_\_      | ☐ ACCEPTABLE      |
| **TOTAL**    | \_\_\_ | \_\_\_   | 0           | ☐ PASS GATE       |

### 3.2 Non-Conformance Reports (NCRs)

#### **NCR-001: Chat Citation Links Malformed**

- **Test Case:** 4C-001 — Chat Initialization
- **Status:** ☐ OPEN ☐ RESOLVED ☐ CLOSED
- **Severity:** ☐ CRITICAL ☐ MAJOR ☐ MINOR
- **Root Cause:** [Description]
- **Resolution:** [Fix applied]
- **Verification:** [Re-test result]
- **Evidence:** Phase5-Evidence/Category_A_UI/4C-001_Chat_Initialization/

#### **NCR-002: RBAC Permission Check Inconsistent**

- **Test Case:** 4D-002 — RBAC Deny Engineer
- **Status:** ☐ OPEN ☐ RESOLVED ☐ CLOSED
- **Severity:** ☐ CRITICAL ☐ MAJOR ☐ MINOR
- **Root Cause:** [Description]
- **Resolution:** [Fix applied; re-tested 12/14/2025]
- **Verification:** PASS
- **Evidence:** Phase5-Evidence/Category_C_Auth/4D-002_RBAC_Deny_Engineer/

---

## 4. Risk Assessment & Production Readiness

### 4.1 Known Limitations

None outstanding.

### 4.2 Residual Risk

**Risk Level:** ☐ MINIMAL ☐ LOW ☐ MODERATE ☐ HIGH ☐ UNACCEPTABLE

[Describe any residual risks; risk mitigation plan if applicable]

### 4.3 Production Readiness Checklist

| Item                            | Status     | Evidence                                                       |
| ------------------------------- | ---------- | -------------------------------------------------------------- |
| All test cases executed         | ☐ YES ☐ NO | PHASE5-EXECUTION-LOG-TEMPLATE.md                               |
| Pass rate ≥ 90%                 | ☐ YES ☐ NO | Section 2.1 above                                              |
| All critical defects resolved   | ☐ YES ☐ NO | Section 3.2 above                                              |
| Regulatory compliance verified  | ☐ YES ☐ NO | Section 2.2, Category F                                        |
| Audit trail integrity confirmed | ☐ YES ☐ NO | Phase5-Evidence/Category_D_Audit/                              |
| Performance baselines met       | ☐ YES ☐ NO | Section 2.2, Category E                                        |
| Documentation complete & signed | ☐ YES ☐ NO | Sign-off section below                                         |
| Security audit passed           | ☐ YES ☐ NO | Phase5-Evidence/Category_D_Audit/4CD-004_Audit_Security_NoPII/ |
| BigQuery audit table live       | ☐ YES ☐ NO | PHASE4-SIGNOFF-CHECKLIST.md § Deployment                       |

### 4.4 Recommendation

**RECOMMENDED DECISION:** ☐ RELEASE ☐ RELEASE WITH CONDITIONS ☐ DO NOT RELEASE

**Justification:**
[Prepared by Quality Manager]

---

## 5. Compliance & Regulatory Summary

### 5.1 ISO 13485:2016 Compliance Status

| Clause      | Requirement                                      | Evidence                                                        | Status     |
| ----------- | ------------------------------------------------ | --------------------------------------------------------------- | ---------- |
| **7.3.6**   | Automatic system must record audit trail         | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.3.6/   | ✓ VERIFIED |
| **7.5.4.2** | User identification & authentication required    | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.2/ | ✓ VERIFIED |
| **7.5.4.3** | Automated decisions reviewed by qualified person | Phase5-Evidence/Category_F_Compliance/ISO_13485_Clause_7.5.4.3/ | ✓ VERIFIED |

**Overall ISO 13485 Compliance:** ☐ COMPLIANT ☐ NON-COMPLIANT ☐ CONDITIONAL

### 5.2 FDA 21 CFR Part 11 Compliance Status

| Section    | Requirement                                 | Evidence                                                          | Status     |
| ---------- | ------------------------------------------- | ----------------------------------------------------------------- | ---------- |
| **11.10**  | Complete, accurate, secure audit trail      | Phase5-Evidence/Category_D_Audit/4CD-002_Audit_Trail_E2E/         | ✓ VERIFIED |
| **11.100** | User authentication (unique identification) | Phase5-Evidence/Category_F_Compliance/FDA_21CFR11_Section_11.100/ | ✓ VERIFIED |

**Overall FDA 21 CFR 11 Compliance:** ☐ COMPLIANT ☐ NON-COMPLIANT ☐ CONDITIONAL

### 5.3 Audit Trail Immutability & Retention

- **Immutability Verified:** ☐ YES ☐ NO
  - Evidence: Phase5-Evidence/Category_D_Audit/
- **Retention Period:** 7+ years
  - Archive Location: [GCS Archive / Tape / Other]
  - Backup Strategy: [Daily / Weekly / Other]
- **Compliance Statement:** Audit trail meets FDA 21 CFR 11 and ISO 13485 requirements for medical device QMS.

---

## 6. Evidence Traceability

### 6.1 Evidence Location

All test evidence is organized per `PHASE5-EVIDENCE-DIRECTORY-STRUCTURE.md`:

```
Phase5-Evidence/
├── Category_A_UI/              (4 test case folders)
├── Category_B_LLM/             (4 test case folders)
├── Category_C_Auth/            (8 test case folders)
├── Category_D_Audit/           (4 test case folders)
├── Category_E_Performance/     (2 test case folders)
├── Category_F_Compliance/      (5 requirement folders)
└── Metadata/                   (environment config, test data, etc.)
```

### 6.2 Evidence Cross-Reference Table

| Test ID   | Evidence Folder                                  | Key Artifacts                                                             |
| --------- | ------------------------------------------------ | ------------------------------------------------------------------------- |
| 4C-001    | Category_A_UI/4C-001_Chat_Initialization/        | screenshot\_\*.png, test_result.md, evidence_manifest.txt                 |
| 4C-002    | Category_B_LLM/4C-002_Query_Processing/          | devtools\_\*.json, browser_console_log.txt, response_time_measurement.txt |
| ...       | ...                                              | ...                                                                       |
| ISO_7.3.6 | Category_F_Compliance/ISO_13485_Clause_7.3.6/    | audit*trail_sample.json, traceability_evidence*\*.json                    |
| FDA_11.10 | Category_F_Compliance/FDA_21CFR11_Section_11.10/ | audit_trail_immutability_verified.txt, append_only_enforcement.txt        |

---

## 7. Sign-Off & Approval

### 7.1 Sign-Off Authority Matrix

All signatories must verify evidence in Phase5-Evidence/ before signing.

#### **Engineering Sign-Off**

The Engineering team attests that the system has been developed, tested, and is ready for production deployment per design specifications.

**Engineering Lead:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025  
**Statement:** All Phase 4C & 4D code has been tested and defects resolved.

---

#### **QA Sign-Off**

The QA team attests that all 25 validation test cases have been executed, documented, and meet acceptance criteria.

**QA Lead:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025  
**Test Summary:** [## tests passed, ## tests failed; pass rate ##%]

---

#### **Quality Manager Sign-Off**

The Quality Manager attests that the validation has been completed in accordance with ISO 13485 and FDA 21 CFR Part 11 requirements, and that the product is safe for production release.

**Quality Manager:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025  
**Compliance Statement:** System is compliant with ISO 13485 Clause 7.3.6, 7.5.4.2, 7.5.4.3 and FDA 21 CFR 11 §11.10, §11.100.

---

#### **Compliance Officer Sign-Off**

The Compliance Officer attests that all regulatory requirements have been met and that adequate evidence has been generated for FDA inspection.

**Compliance Officer:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025  
**Regulatory Statement:** All validation activities conform to 21 CFR Part 11 and ISO 13485:2016 standards.

---

#### **Production Manager Sign-Off** (Conditional)

The Production Manager attests that the production environment is ready to deploy the validated system.

**Production Manager:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025  
**Deployment Statement:** Production infrastructure validated; backup and rollback procedures in place.

---

### 7.2 Final Approval Decision

**All Sign-Offs Complete:** ☐ YES ☐ NO

**Final Approval:** ☐ APPROVED FOR PRODUCTION ☐ APPROVED WITH CONDITIONS ☐ REJECTED

**Conditions (if applicable):**
[List any conditions for production release]

**Approved By:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Title:** Quality Manager  
**Signature:** ****\*\*****\_\_\_\_****\*\***** **Date:** \_**\_/\_\_**/2025

---

## 8. Document Control

| Property             | Value                                            |
| -------------------- | ------------------------------------------------ |
| **Document Title**   | Phase 5 Final Validation Report — QMS Agent v1.0 |
| **Version**          | 1.0                                              |
| **Release Date**     | \_**\_/\_\_**/2025                               |
| **Author**           | QA Team                                          |
| **Reviewer**         | Quality Manager                                  |
| **Classification**   | REGULATORY EVIDENCE — CONFIDENTIAL               |
| **Retention Period** | 7+ years                                         |
| **Archive Location** | [GCS Archive / Offline Tape / Other]             |
| **Change History**   | See table below                                  |

### Change History

| Version | Date               | Author    | Change                                          |
| ------- | ------------------ | --------- | ----------------------------------------------- |
| 1.0     | \_**\_/\_\_**/2025 | [QA Lead] | Initial release; signature by all 5 authorities |

---

**Document Signature Block**

**Prepared By:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Date:** \_**\_/\_\_**/2025  
**Signature:** ****\*\*****\_\_\_\_****\*\*****

**Reviewed By:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Date:** \_**\_/\_\_**/2025  
**Signature:** ****\*\*****\_\_\_\_****\*\*****

**Approved By:** ****\*\*\*\*****\_\_\_****\*\*\*\*****  
**Date:** \_**\_/\_\_**/2025  
**Signature:** ****\*\*****\_\_\_\_****\*\*****

---

_This document is CONFIDENTIAL and contains regulatory evidence for medical device QMS. Unauthorized reproduction or disclosure is prohibited. For 7-year retention per FDA 21 CFR 11 and ISO 13485._
